Cross-institution positioning
Aug 6, 2026Strong institutional accumulation. 3 accumulating, 2 exited across 5 comparable institutions.
Source: Schedule 13 researchDyne Therapeutics, Inc.
Latest stored close $15.97 as of Oct 7, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Strong institutional accumulation. 3 accumulating, 2 exited across 5 comparable institutions.
Source: Schedule 13 research2 increased/new, 0 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsOver the last 90 days, SEC-coded non-derivative P/S activity includes 1 purchase by 1 reporting owner and 17 sales by 6 reporting owners. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/56 non-amendment material events in the last 90 days; 2 capital-related filing/events; Latest classified evidence: Regulation FD disclosure. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataNet income -61.1% YoY; Free cash flow -37.3% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 39% through its reported 52-week range; +39.2% over one year.
Source: Stored historical price seriesFiled Aug 6, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Posner Brian S | POpen-market or private purchase | Common Stock | 2.5K | $16.00 | Direct | Oct 6, 2026 |
| Sep 8, 2026 | Cox John | SOpen-market or private sale | Common Stock | 5.7K | $18.88 | Direct | Sep 8, 2026 |
| Sep 8, 2026 | Kerr Douglas | SOpen-market or private sale | Common Stock | 1.3K | $18.88 | Direct | Sep 8, 2026 |
| Sep 8, 2026 | Friedl-Naderer Johanna | SOpen-market or private sale | Common Stock | 185 | $18.88 | Direct | Sep 8, 2026 |
| Sep 4, 2026 | Kerr Douglas | SOpen-market or private sale | Common Stock | 3.7K | $24.35 | Direct | Sep 8, 2026 |
| Sep 4, 2026 | Friedl-Naderer Johanna | SOpen-market or private sale | Common Stock | 900 | $24.35 | Direct | Sep 8, 2026 |
| Aug 14, 2026 | Rhodes Jason P | SOpen-market or private sale | Common Stock | 322.5K | $25.00 | Indirect | Aug 17, 2026 |
| Aug 14, 2026 | Rhodes Jason P | SOpen-market or private sale | Common Stock | 478.4K | $25.00 | Indirect | Aug 17, 2026 |
| Aug 14, 2026 | Rhodes Jason P | SOpen-market or private sale | Common Stock | 1.4M | $25.00 | Indirect | Aug 17, 2026 |
| Aug 13, 2026 | Rhodes Jason P | SOpen-market or private sale | Common Stock | 63.6K | $26.20 | Indirect | Aug 17, 2026 |
| Aug 13, 2026 | Rhodes Jason P | SOpen-market or private sale | Common Stock | 94.4K | $26.20 | Indirect | Aug 17, 2026 |
| Aug 13, 2026 | Rhodes Jason P | SOpen-market or private sale | Common Stock | 268.4K | $26.20 | Indirect | Aug 17, 2026 |
| Aug 13, 2026 | Lucera Erick | SOpen-market or private sale | Common Stock | 1.8K | $26.28 | Direct | Aug 17, 2026 |
| Aug 13, 2026 | Cox John | SOpen-market or private sale | Common Stock | 5.0K | $26.28 | Direct | Aug 17, 2026 |
| Aug 13, 2026 | Kerr Douglas | SOpen-market or private sale | Common Stock | 1.6K | $26.28 | Direct | Aug 17, 2026 |
| Aug 13, 2026 | Friedl-Naderer Johanna | SOpen-market or private sale | Common Stock | 226 | $26.28 | Direct | Aug 17, 2026 |
| Jul 27, 2026 | Kersten Dirk | SOpen-market or private sale | Common Stock | 5.4K | $26.04 | Indirect | Jul 29, 2026 |
| Jul 27, 2026 | Kersten Dirk | SOpen-market or private sale | Common Stock | 256.1K | $25.50 | Indirect | Jul 29, 2026 |
| Jul 7, 2026 | Rhodes Jason P | SOpen-market or private sale | Common Stock | 5.0K | $23.61 | Indirect | Jul 8, 2026 |
| Jul 7, 2026 | Rhodes Jason P | SOpen-market or private sale | Common Stock | 11.7K | $23.62 | Indirect | Jul 8, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Sep 29, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Jul 29, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jul 22, 2026 | 424B5 | — | Prospectus filing | Capital-related | Filing |
| Jul 22, 2026 | 8-K | 1.01, 8.01, 9.01 | Material definitive agreement; Other event; Financial statements / exhibits | — | Filing |
| Jul 21, 2026 | 424B5 | — | Prospectus filing | Capital-related | Filing |
| Jul 20, 2026 | 8-K | 8.01 | Other event | — | Filing |
| Jun 22, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| Jun 17, 2026 | 8-K | 1.01, 2.03 | Material definitive agreement; New direct financial obligation | Debt | Filing |
| Jun 8, 2026 | 8-K | 5.07 | Shareholder vote results | — | Filing |
| Jun 3, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| May 11, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Fidelity / FMR CIK0000315066 | Jun 30, 2026 observed Aug 6, 2026 filed · 37d Schedule 13G amendment | Reported accumulation | 11.2K +2.3K | 6.80% -5.20 pts | $22.21 | $25.88 | $15.97 |
| BlackRock CIK0002012383 | Jun 30, 2026 observed Jul 28, 2026 filed · 28d Schedule 13G amendment | Reported accumulation | 11.5M +4.9M | 12.00% +6.20 pts | $22.21 | $25.90 | $15.97 |
| T. Rowe Price Investment Management CIK0001897612 | Mar 31, 2026 observed May 15, 2026 filed · 45d Schedule 13G amendment | Reported accumulation | 30.8M +4.2M | 18.70% +2.50 pts | $18.13 | $17.29 | $15.97 |
Compare DYN with other securities showing similar institutional activity or recent accumulation across several tracked institutions.